Trial Profile
Validating the Predictive Value (of Response to Rituximab Induction and Maintenance) of the FCGR3A 158V/F Polymorphism Using Complimentary Genotyping Methods
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Pharmacogenomic; Therapeutic Use
- 18 May 2017 New trial record
- 16 May 2017 Status changed from not yet recruiting to completed.